-- Simcere Pharmaceutical's (HKG:2096) resubmitted new drug application for Rademikibart was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The acceptance is for the use of the drug, which was jointly developed by the firm and Connect Biopharma Hong Kong, for the treatment of atopic dermatitis in adults and adolescents.